<p>Exelixis（納斯達克股票代碼：EXEL）將於 2026 年 2 月 10 日發佈季度財報。以下是投資者在公告前的簡要概述。</p>
<p>分析師預計 Exelixis 的 <strong>每股收益</strong>（EPS）為 0.76 美元。</p>
<p>市場期待 Exelixis 的公告，寄希望於超出預期的消息，併為下個季度提供樂觀的指引。</p>
<p>新投資者需要理解，指引可能是股價的重要驅動因素。</p>
<h3>財報歷史快照</h3>
<p>該公司在上個季度的每股收益超出預期 0.15 美元，導致次日股價上漲 6.52%。</p>
<p>以下是 Exelixis 的過去表現及其相應的價格變化：</p>
<table>
<thead>
<tr>
<th><strong>季度</strong></th>
<th align="right"><strong>2025 年第三季度</strong></th>
<th align="right"><strong>2025 年第二季度</strong></th>
<th align="right"><strong>2025 年第一季度</strong></th>
<th align="right"><strong>2024 年第四季度</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS 預估</strong></td>
<td align="right">0.63</td>
<td align="right">0.61</td>
<td align="right">0.44</td>
<td align="right">0.49</td>
</tr>
<tr>
<td><strong>EPS 實際</strong></td>
<td align="right">0.78</td>
<td align="right">0.75</td>
<td align="right">0.62</td>
<td align="right">0.55</td>
</tr>
<tr>
<td><strong>價格變化 %</strong></td>
<td align="right">7.00</td>
<td align="right">-17.00</td>
<td align="right">21.00</td>
<td align="right">0.00</td>
</tr>
</tbody>
</table>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770656505_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="eps graph" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770656505_0.png"/></p>
<h3>Exelixis 股價分析</h3>
<p>截至 2 月 6 日，Exelixis 的股價為 43.9 美元。在過去 52 周內，股價上漲了 33.59%。鑑於這些回報通常是積極的，長期股東在此次財報發佈前可能持樂觀態度。</p>
<h3>分析師對 Exelixis 的看法</h3>
<p>瞭解市場情緒和行業內的預期對投資者至關重要。此分析深入探討了關於 Exelixis 的最新見解。</p>
<p>Exelixis 的共識評級為買入，基於 6 位分析師的評級。平均一年目標價為 49.5 美元，潛在上漲空間為 12.76%。</p>
<h3>同業評級比較</h3>
<p>以下分析聚焦於 Exelixis 及 BioMarin Pharmaceutical 這三家知名行業公司的分析師評級和平均一年目標價，提供對其相對錶現預期和市場定位的見解。</p>
<ul>
<li>分析師目前對 BioMarin Pharmaceutical 的評級為買入，平均一年目標價為 80.4 美元，暗示潛在上漲空間為 83.14%。</li>
</ul>
<h3>同業指標摘要</h3>
<p>在同業分析摘要中，展示了 Exelixis 及 BioMarin Pharmaceutical 的重要指標，揭示了它們在行業中的相對地位，並提供了對其市場位置和比較表現的有價值見解。</p>
<table>
<thead>
<tr>
<th>公司</th>
<th>共識</th>
<th>收入增長</th>
<th>毛利潤</th>
<th>股本回報率</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exelixis</td>
<td>買入</td>
<td>10.79%</td>
<td>5.7918 億美元</td>
<td>9.23%</td>
</tr>
<tr>
<td>BioMarin Pharmaceutical</td>
<td>買入</td>
<td>4.08%</td>
<td>6.3605 億美元</td>
<td>-0.51%</td>
</tr>
</tbody>
</table>
<p>關鍵要點：</p>
<p>Exelixis 在收入增長和毛利潤方面高於其同行。然而，其股本回報率低於同行。</p>
<h3>關於 Exelixis 的所有信息</h3>
<p>Exelixis Inc 是一家生物製藥公司，專注於發現、開發和商業化癌症治療方案。其分子 cabozantinib 被用於治療轉移性髓樣甲狀腺癌，商品名為 Cometriq，並用於治療腎癌和肝癌，商品名為 Cabometyx。Exelixis 及其合作伙伴羅氏還推出了 Cotellic 用於黑色素瘤的治療。</p>
<h3>財務洞察：Exelixis</h3>
<p><strong>市值：</strong> 由於市值受限，該公司在行業平均水平以下。這反映出其相對於同行的規模較小。</p>
<p><strong>收入增長：</strong> Exelixis 在過去 3 個月的收入增長顯著。截至 2025 年 9 月 30 日，該公司的收入增長率約為 <strong>10.79%</strong>。這表明公司的營業收入有了顯著增加。與行業同行相比，該公司的增長率低於醫療保健行業的平均水平。</p>
<p><strong>淨利潤率：</strong> Exelixis 的財務實力體現在其卓越的淨利潤率上，超過行業平均水平。該公司的淨利潤率達到 <strong>32.38%</strong>，展現出強勁的盈利能力和有效的成本管理。</p>
<p><strong>股本回報率（ROE）：</strong> Exelixis 的財務實力體現在其卓越的 ROE 上，超過行業平均水平。該公司的 ROE 達到 <strong>9.23%</strong>，展現出對股本資本的高效利用和強健的財務健康。</p>
<p><strong>資產回報率（ROA）：</strong> Exelixis 的 ROA 超過行業標準，突顯出公司的卓越財務表現。該公司的 ROA 達到 <strong>7.04%</strong>，有效利用資產以獲得最佳回報。</p>
<p><strong>債務管理：</strong> Exelixis 的債務與股本比率低於行業平均水平。該比率為 <strong>0.08</strong>，公司較少依賴債務融資，保持了債務與股本之間更健康的平衡，這對投資者來説是一個積極的信號。</p>
<p>要跟蹤 Exelixis 的所有財報發佈，請訪問我們網站的財報日曆。</p>
<p><em>本文由 Benzinga 的自動內容引擎生成，並經過編輯審核。</em></p>

紐交所高增長板生物技術指數 ETF - First Trust

醫藥突破 ETF - ALPS

標普全球醫療股指數 ETF - iShares

<p>Exelixis（納斯達克代碼：EXEL）定於 2026 年 2 月 10 日發佈季度財報，分析師預計每股收益（EPS）為 0.76 美元。該公司表現積極，上個季度超出 EPS 預期，導致股價上漲 6.52%。目前股價為 43.9 美元，過去一年上漲了 33.59%。分析師對該股票給予 “買入” 評級，目標價為 49.5 美元，顯示出潛在的上漲空間。與同行相比，Exelixis 在收入增長和淨利潤率方面表現出色，展現出強勁的財務健康狀況</p>

<p>Exelixis (NASDAQ: EXEL) will release its quarterly earnings report on Tuesday, 2026-02-10. Here's a brief overview for investors ahead of the announcement.</p>
<div class="lb-trans"><p>Exelixis（納斯達克股票代碼：EXEL）將於 2026 年 2 月 10 日發佈季度財報。以下是投資者在公告前的簡要概述。</p>
</div><p>Analysts anticipate Exelixis to report an <strong>earnings per share</strong> (EPS) of $0.76.</p>
<div class="lb-trans"><p>分析師預計 Exelixis 的 <strong>每股收益</strong>（EPS）為 0.76 美元。</p>
</div><p>The market awaits Exelixis's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<div class="lb-trans"><p>市場期待 Exelixis 的公告，寄希望於超出預期的消息，併為下個季度提供樂觀的指引。</p>
</div><p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<div class="lb-trans"><p>新投資者需要理解，指引可能是股價的重要驅動因素。</p>
</div><h3>Earnings History Snapshot</h3>
<div class="lb-trans"><h3>財報歷史快照</h3>
</div><p>The company's EPS beat by $0.15 in the last quarter, leading to a 6.52% increase in the share price on the following day.</p>
<div class="lb-trans"><p>該公司在上個季度的每股收益超出預期 0.15 美元，導致次日股價上漲 6.52%。</p>
</div><p>Here's a look at Exelixis's past performance and the resulting price change:</p>
<div class="lb-trans"><p>以下是 Exelixis 的過去表現及其相應的價格變化：</p>
</div><table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th align="right"><strong>Q3 2025</strong></th>
<th align="right"><strong>Q2 2025</strong></th>
<th align="right"><strong>Q1 2025</strong></th>
<th align="right"><strong>Q4 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td align="right">0.63</td>
<td align="right">0.61</td>
<td align="right">0.44</td>
<td align="right">0.49</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td align="right">0.78</td>
<td align="right">0.75</td>
<td align="right">0.62</td>
<td align="right">0.55</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td align="right">7.00</td>
<td align="right">-17.00</td>
<td align="right">21.00</td>
<td align="right">0.00</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th><strong>季度</strong></th>
<th align="right"><strong>2025 年第三季度</strong></th>
<th align="right"><strong>2025 年第二季度</strong></th>
<th align="right"><strong>2025 年第一季度</strong></th>
<th align="right"><strong>2024 年第四季度</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS 預估</strong></td>
<td align="right">0.63</td>
<td align="right">0.61</td>
<td align="right">0.44</td>
<td align="right">0.49</td>
</tr>
<tr>
<td><strong>EPS 實際</strong></td>
<td align="right">0.78</td>
<td align="right">0.75</td>
<td align="right">0.62</td>
<td align="right">0.55</td>
</tr>
<tr>
<td><strong>價格變化 %</strong></td>
<td align="right">7.00</td>
<td align="right">-17.00</td>
<td align="right">21.00</td>
<td align="right">0.00</td>
</tr>
</tbody>
</table>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770656505_0.png" alt="eps graph" original-src="https://www.benzinga.com/files/images/story/2026/1770656505_0.png"/></p>
<h3>Exelixis Share Price Analysis</h3>
<div class="lb-trans"><h3>Exelixis 股價分析</h3>
</div><p>Shares of Exelixis were trading at $43.9 as of February 06. Over the last 52-week period, shares are up 33.59%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.</p>
<div class="lb-trans"><p>截至 2 月 6 日，Exelixis 的股價為 43.9 美元。在過去 52 周內，股價上漲了 33.59%。鑑於這些回報通常是積極的，長期股東在此次財報發佈前可能持樂觀態度。</p>
</div><h3>Analysts' Perspectives on Exelixis</h3>
<div class="lb-trans"><h3>分析師對 Exelixis 的看法</h3>
</div><p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Exelixis.</p>
<div class="lb-trans"><p>瞭解市場情緒和行業內的預期對投資者至關重要。此分析深入探討了關於 Exelixis 的最新見解。</p>
</div><p>The consensus rating for Exelixis is Buy, based on 6 analyst ratings. With an average one-year price target of $49.5, there's a potential 12.76% upside.</p>
<div class="lb-trans"><p>Exelixis 的共識評級為買入，基於 6 位分析師的評級。平均一年目標價為 49.5 美元，潛在上漲空間為 12.76%。</p>
</div><h3>Peer Ratings Comparison</h3>
<div class="lb-trans"><h3>同業評級比較</h3>
</div><p>The following analysis focuses on the analyst ratings and average 1-year price targets of and BioMarin Pharmaceutical, three prominent industry players, providing insights into their relative performance expectations and market positioning.</p>
<div class="lb-trans"><p>以下分析聚焦於 Exelixis 及 BioMarin Pharmaceutical 這三家知名行業公司的分析師評級和平均一年目標價，提供對其相對錶現預期和市場定位的見解。</p>
</div><ul>
<li>Analysts currently favor an Buy trajectory for BioMarin Pharmaceutical, with an average 1-year price target of $80.4, suggesting a potential 83.14% upside.</li>
</ul>
<div class="lb-trans"><ul>
<li>分析師目前對 BioMarin Pharmaceutical 的評級為買入，平均一年目標價為 80.4 美元，暗示潛在上漲空間為 83.14%。</li>
</ul>
</div><h3>Peer Metrics Summary</h3>
<div class="lb-trans"><h3>同業指標摘要</h3>
</div><p>Within the peer analysis summary, vital metrics for and BioMarin Pharmaceutical are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<div class="lb-trans"><p>在同業分析摘要中，展示了 Exelixis 及 BioMarin Pharmaceutical 的重要指標，揭示了它們在行業中的相對地位，並提供了對其市場位置和比較表現的有價值見解。</p>
</div><table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exelixis</td>
<td>Buy</td>
<td>10.79%</td>
<td>$579.18M</td>
<td>9.23%</td>
</tr>
<tr>
<td>BioMarin Pharmaceutical</td>
<td>Buy</td>
<td>4.08%</td>
<td>$636.05M</td>
<td>-0.51%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>公司</th>
<th>共識</th>
<th>收入增長</th>
<th>毛利潤</th>
<th>股本回報率</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exelixis</td>
<td>買入</td>
<td>10.79%</td>
<td>5.7918 億美元</td>
<td>9.23%</td>
</tr>
<tr>
<td>BioMarin Pharmaceutical</td>
<td>買入</td>
<td>4.08%</td>
<td>6.3605 億美元</td>
<td>-0.51%</td>
</tr>
</tbody>
</table>
</div><p>Key Takeaway:</p>
<div class="lb-trans"><p>關鍵要點：</p>
</div><p>Exelixis ranks higher than its peers in terms of revenue growth and gross profit. However, it has a lower return on equity compared to its peers.</p>
<div class="lb-trans"><p>Exelixis 在收入增長和毛利潤方面高於其同行。然而，其股本回報率低於同行。</p>
</div><h3>All You Need to Know About Exelixis</h3>
<div class="lb-trans"><h3>關於 Exelixis 的所有信息</h3>
</div><p>Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.</p>
<div class="lb-trans"><p>Exelixis Inc 是一家生物製藥公司，專注於發現、開發和商業化癌症治療方案。其分子 cabozantinib 被用於治療轉移性髓樣甲狀腺癌，商品名為 Cometriq，並用於治療腎癌和肝癌，商品名為 Cabometyx。Exelixis 及其合作伙伴羅氏還推出了 Cotellic 用於黑色素瘤的治療。</p>
</div><h3>Financial Insights: Exelixis</h3>
<div class="lb-trans"><h3>財務洞察：Exelixis</h3>
</div><p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<div class="lb-trans"><p><strong>市值：</strong> 由於市值受限，該公司在行業平均水平以下。這反映出其相對於同行的規模較小。</p>
</div><p><strong>Revenue Growth:</strong> Exelixis's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2025, the company achieved a revenue growth rate of approximately <strong>10.79%</strong>. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<div class="lb-trans"><p><strong>收入增長：</strong> Exelixis 在過去 3 個月的收入增長顯著。截至 2025 年 9 月 30 日，該公司的收入增長率約為 <strong>10.79%</strong>。這表明公司的營業收入有了顯著增加。與行業同行相比，該公司的增長率低於醫療保健行業的平均水平。</p>
</div><p><strong>Net Margin:</strong> Exelixis's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>32.38%,</strong> the company showcases strong profitability and effective cost management.</p>
<div class="lb-trans"><p><strong>淨利潤率：</strong> Exelixis 的財務實力體現在其卓越的淨利潤率上，超過行業平均水平。該公司的淨利潤率達到 <strong>32.38%</strong>，展現出強勁的盈利能力和有效的成本管理。</p>
</div><p><strong>Return on Equity (ROE):</strong> Exelixis's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>9.23%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<div class="lb-trans"><p><strong>股本回報率（ROE）：</strong> Exelixis 的財務實力體現在其卓越的 ROE 上，超過行業平均水平。該公司的 ROE 達到 <strong>9.23%</strong>，展現出對股本資本的高效利用和強健的財務健康。</p>
</div><p><strong>Return on Assets (ROA):</strong> Exelixis's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>7.04%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<div class="lb-trans"><p><strong>資產回報率（ROA）：</strong> Exelixis 的 ROA 超過行業標準，突顯出公司的卓越財務表現。該公司的 ROA 達到 <strong>7.04%</strong>，有效利用資產以獲得最佳回報。</p>
</div><p><strong>Debt Management:</strong> Exelixis's debt-to-equity ratio is below the industry average. With a ratio of <strong>0.08</strong>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<div class="lb-trans"><p><strong>債務管理：</strong> Exelixis 的債務與股本比率低於行業平均水平。該比率為 <strong>0.08</strong>，公司較少依賴債務融資，保持了債務與股本之間更健康的平衡，這對投資者來説是一個積極的信號。</p>
</div><p>To track all earnings releases for Exelixis visit their earnings calendar on our site.</p>
<div class="lb-trans"><p>要跟蹤 Exelixis 的所有財報發佈，請訪問我們網站的財報日曆。</p>
</div><p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>
<div class="lb-trans"><p><em>本文由 Benzinga 的自動內容引擎生成，並經過編輯審核。</em></p>
</div>

伊克力西斯未來收益展望